Some of the names on the move ahead of the open.» Read More
Cramer makes the call on viewers' favorite stocks.
The Lightning Round is extended in this new CNBC.com exclusive feature.
Investors are worried about a recession again. So CNBC asked the experts for some recession-proof stock picks.
The medical device field has its problems -- but Jan Wald thinks the stocks of medical device makers may be excellent defensive plays in the current market environment. "Valuations of these stocks are pretty low at this point," the Stanford Group managing director told CNBC...
Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.
An unprecedented late-day rally reversed morning losses and sent the Dow higher by 300 points - all thanks to the banks and brokers. Could this move mean a bottom or is it nothing more an oversold rally?
Stocks snapped a five-day losing streak, with the Dow surging nearly 300 points on optimism that a government plan to rescue ailing bond insurers is taking shape and could prevent billions more in credit losses.
Goldman Sachs analysts say stock investors should look to larger cap and defensive sectors as a way to play the uncertainty of presidential primary season. While they say the major party nominees should become clear by "Super Duper Tuesday," there is greater electoral and policy uncertainty in this Presidential race because there are no incumbents running.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
Like precision radar, The Fast Money Five zero in on three hot trades. Find out how they're playing excessive write-downs, a highly anticipated decision from the FDA and avoiding a visit from the tax man!
Abbott Laboratories said on Tuesday it will lay off about 1,200 workers in California and Ireland to compensate for a contracting drug-coated heart stent market and manufacturingimprovements.
Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Two top traders offered a mixed bag of stocks, across several sectors, to help investors prepare for market turbulence in the week ahead.
Abbott Laboratories moved closer to joining the U.S. market for drug-coated heart stents on Thursday as an advisory panel backed the company's experimental device.
Abbott Laboratories on Wednesday said third-quarter earnings were little changed due to special charges, but the company reported sharply higher sales of its prescription drugs and medical devices.
By the end of the coming week, the corporate earnings picture will be clear and it may not necessarily be one the stock market likes.
Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.
BREAKING: Reuters reports FDA panel backs drug-coated stents made by Medtronic (MDT).
A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.
Abbott Laboratories posted higher second-quarter earnings Wednesday on increased sales of its prescription drugs, with global revenue from arthritis treatment Humira jumping 50%.